Skip to main content

Currently Skimming:

Appendix B: Pertussis and Rubella Vaccines: A Brief Chronology
Pages 320-332

The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.


From page 320...
... pertussis. In ensuing years, such vaccines are developed, and used in children, by Bordet and Gengou in 1912, Charles Nicolle of the Pasteur Institute in Tunis in 1913, and Thorvald Madsen of the Danish State Serum Institute in Copenhagen in 1914, among others (Chase, 19821.
From page 321...
... 1947- The first published reports appear of irreversible brain damage 1948 after whole-cell pertussis vaccine (Brody and Sorley, 1947; Byers and Moll, 1948~. Although the Brody and Sorley report de scribes one case only, it leads to the first warnings that pertussis vaccine should not be administered to those with a known neuro logic disorder.
From page 322...
... In the United States, public health clinics using federally purchased vaccines are required to have parents sign an "important information statement" before their child can be vaccinated (Courter and Fisher, 1985~. The Monitoring System for Illness Following Immunization (MSIFI)
From page 323...
... The Senate Subcommittee on Investigations and General Oversight, chaired by Senator Paula Hawkins, holds hearings "to examine adverse drug reactions from immunization, federal efforts in preventive medicine, and characteristics of certain diseases" (Courter and Fisher, 1985; Gonzalez, 1982~. The British Child Health and Education Study is published (Butler et al., 1982~.
From page 324...
... Only two pharmaceutical companies in the United States continue to sell pertussis vaccines. The National Childhood Vaccine Injury Compensation Act is introduced in the U.S.
From page 325...
... to advise the director of the NVP; the National Vaccine Injury Compensation Program (VICP) to evaluate claims of injury from vaccines and provide compensation where justified; and the Advisory Commission on Childhood Vaccines (ACCV)
From page 326...
... The IOM holds a CDC-sponsored workshop on the National Childhood Encephalopathy Study (Marcuse and Wentz, 1990~. 1990 The IOM Committee to Review the Adverse Consequences of Pertussis and Rubella Vaccines is appointed in December 1989 and meets for the first time in January 1990.
From page 327...
... The epidemic and its aftermath lend impetus to the search for a rubella vaccine and are instrumental in the initial approval of Title XIX (the Medicaid provisions) of the Social Security Act of 1965 and in subsequent amendments to Title XIX, the Early and Periodic Screening, Diagnosis, and Treatment program.
From page 328...
... RA 27/3, a human diploid fibroblast vaccine developed in the United States, is licensed in several European countries (Plotkin, 1988~. Reports of possible serious adverse events following rubella vaccination begin to be published.
From page 329...
... In the same month, the committee sponsors a public meet ing in Washington, D.C., to solicit medical and other scientific data and comments on the nature, frequency, and circumstances of adverse events following Pertussis and rubella vaccines. In May, it sponsors a workshop on Possible Adverse Consequences of Pertussis and Rubella Vaccines.
From page 330...
... 1985. Persistent rubella virus infection of human synovial cells cultured in vitro.
From page 331...
... 1971. Immunologic response, virus excretion and joint reactions with rubella vaccine: a study of adolescent girls and young women given live attenuated virus vaccine (HPV-77:DE-5)
From page 332...
... 1972. Recurrent joint symptoms in children vaccinated with HPV-77DK12 rubella vaccine.


This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
More information on Chapter Skim is available.